Global Oligonucleotide Therapeutics Market Growth (Status and Outlook) 2025-2031

The global Oligonucleotide Therapeutics market size is predicted to grow from US$ 7372 million in 2025 to US$ 9247 million in 2031; it is expected to grow at a CAGR of 3.8% from 2025 to 2031.

Oligonucleotide therapeutics are a class of precision medicines composed of short DNA or RNA sequences designed to specifically target and modulate the expression of genes involved in disease processes. These therapies can act by silencing, inhibiting, or correcting genetic abnormalities at the molecular level, offering a highly targeted approach to treat various conditions such as genetic disorders, cancers, and viral infections. Oligonucleotide therapeutics include antisense oligonucleotides, small interfering RNA (siRNA), and aptamers, and they represent a promising area of drug development due to their ability to address previously untreatable diseases.

Key driver of the oligonucleotide therapeutics market is the growing prevalence of genetic and rare diseases that require precise and targeted treatment options. Advances in genomics and personalized medicine have fueled interest in oligonucleotide therapies, which can directly modulate gene expression and offer solutions for conditions that were previously difficult to treat. The success of approved oligonucleotide drugs, such as antisense oligonucleotides and siRNA therapies, has increased confidence in this field, leading to more investments and research in developing novel treatments for a wide range of diseases, including cancers and neurological disorders.

One significant challenge in the oligonucleotide therapeutics market is the complexity of delivering these molecules effectively to target cells or tissues. Oligonucleotides are large, negatively charged molecules that face hurdles in stability, bioavailability, and efficient cellular uptake. Developing delivery systems that can ensure targeted and sustained delivery while minimizing immune responses or off-target effects remains a critical challenge. Additionally, the high costs associated with research, development, and manufacturing of oligonucleotide-based drugs pose financial challenges, limiting accessibility and widespread adoption, especially in resource-constrained healthcare settings.

Europe is the largest consumption place, with a consumption market share nearly 44.61% in 2023. Following Europe, North Americas is the second largest consumption place with the consumption market share of 34.9%. The global key companies of oligonucleotide therapeutics include Pfizer, Moderna Therapeutics, BioNTech, Biogen, Alnylam, Sarepta Therapeutics, Jazz Pharmaceuticals, Nippon Shinyaku, Novartis, Sobi, Ionis Pharmaceuticals, etc. In 2023, the global top five players had a share approximately 97.87% in terms of revenue.

LPI (LP Information)' newest research report, the “Oligonucleotide Therapeutics Industry Forecast” looks at past sales and reviews total world Oligonucleotide Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Oligonucleotide Therapeutics sales for 2025 through 2031. With Oligonucleotide Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oligonucleotide Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Oligonucleotide Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oligonucleotide Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oligonucleotide Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oligonucleotide Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oligonucleotide Therapeutics.

This report presents a comprehensive overview, market shares, and growth opportunities of Oligonucleotide Therapeutics market by product type, application, key players and key regions and countries.

Segmentation by Type:
Antisense Oligonucleotides (ASO)
siRNA
mRNA

Segmentation by Application:
Neuromuscular Diseases
hATTR
COVID-19
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna

Please note: The report will take approximately 2 business days to prepare and deliver.